文献速递脑血管病

18F氟美他莫PET辅助脑淀粉样血管病分类:一项多中心研究

18FFlutemetamol-PET Aided Classification of Cerebral Amyloid Angiopathy: A Multicenter Study.
PubMed 文献 · Neurology · 2024-07-31

该多中心研究纳入47例伴脑出血、蛛网膜下腔出血、短暂局灶性神经发作或认知障碍且MRI显示脑淀粉样血管病特征的患者,用18F氟美他莫PET将混合型小动脉硬化+脑淀粉样血管病重新分类。PET定义的脑淀粉样血管病/淀粉样病理组复合结局和脑出血发生率均高于小动脉硬化为主组,提示PET有助于风险分层。

要点

  • 18F氟美他莫PET可将混合型小动脉硬化+脑淀粉样血管病重新分类为脑淀粉样血管病/淀粉样病理组和小动脉硬化为主组。
  • 脑淀粉样血管病/淀粉样病理组复合结局43.9 vs 小动脉硬化为主组11.1事件/100患者年(p=0.039)。
  • 脑淀粉样血管病/淀粉样病理组脑出血36.5 vs 小动脉硬化为主组5.6事件/100患者年(p=0.04)。

核心结论

  • 18F氟美他莫PET成像有助于将混合型小动脉硬化+脑淀粉样血管病重新分类为脑淀粉样血管病/淀粉样病理组和小动脉硬化为主组,并对长期复发事件风险有提示意义。

研究设计与样本

  • 研究纳入2家机构2018年至2023年连续收治的自发性症状性脑出血、蛛网膜下腔出血、短暂局灶性神经发作或认知障碍且MRI显示脑淀粉样血管病特征的患者。
  • 所有患者接受脑MRI含磁敏感加权成像和18F氟美他莫PET成像,随访至少1年。
  • 共纳入47例患者,根据PET和MRI成像,38例被重新分类为脑淀粉样血管病/淀粉样病理组,9例为小动脉硬化为主组。

主要发现

  • 脑淀粉样血管病/淀粉样病理组与小动脉硬化为主组心血管危险因素相似,但前者脑叶微出血负荷显著更高。
  • 脑淀粉样血管病/淀粉样病理组复合结局发生率43.9 vs 小动脉硬化为主组11.1事件/100患者年(p=0.039)。
  • 脑淀粉样血管病/淀粉样病理组脑出血发生率36.5 vs 小动脉硬化为主组5.6事件/100患者年(p=0.04)。

关键数值与推荐

  • 复合结局包括死亡、脑出血、缺血性卒中、蛛网膜下腔出血、短暂局灶性神经发作。
  • 本研究提供IV级证据,表明18F氟美他莫PET可区分脑淀粉样血管病+小动脉硬化与小动脉硬化为主病理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cerebral amyloid angiopathy (CAA)-related features on neuroimaging often coexist with signs of arteriolosclerosis-small vessel disease on neuroimaging in people with intracranial hemorrhage (ICH). This study aimed at defining the value of amyloid pathology detected by 18Fflutemetamol PET in reclassification and stratification of risk of bleeding in people with mixed CAA-arteriolosclerosis features. METHODS: We included consecutive patients admitted to 2 institutions (2018-2023) with spontaneous symptomatic ICH, subarachnoid hemorrhage (SAH), transient focal neurologic episodes (TFNE), or cognitive impairment and MRI showing CAA hallmarks. All patients underwent brain magnetic resonance imaging (MRI) with susceptibility weighted imaging and 18Fflutemetamol PET imaging and were followed up for at least 1 year. We compared cases with CAA and arteriolosclerosis + CAA features and defined long-term outcomes (composite outcome including death, ICH, ischemic stroke, SAH, TFNE) depending on PET status (CAA/amyloid pathology vs arteriolosclerosis-predominant groups). RESULTS: Among 47 patients, according to PET and MRI imaging, 38 patients were reclassified in the CAA/amyloid pathology group and 9 in the arteriolosclerosis-predominant group, with similar cardiovascular risk factors but a significantly higher lobar microbleed burden for the former group. The CAA/amyloid pathology group had higher rates of composite outcome (43.9 vs 11.1 events per 100 patient-year; p = 0.039) and ICH (36.5 vs 5.6 events per 100 patient-years; p = 0.04) compared with the arteriolosclerosis-predominant group. DISCUSSION: 18FFlutemetamol PET imaging can help in reclassification of mixed arteriolosclerosis + CAA into CAA/amyloid pathology and arteriolosclerosis-predominant, with implications on long-term risk of recurrent events. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that 18Fflutemetamol PET can distinguish between CAA + arteriolosclerosis and arteriolosclerosis-predominant pathology.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Romoli M, Marinoni G, Tagliabue L, et al. 18FFlutemetamol-PET Aided Classification of Cerebral Amyloid Angiopathy: A Multicenter Study. Neurology. 2024. PMID: 39083717. doi:10.1212/WNL.0000000000209719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。